282 related articles for article (PubMed ID: 35623728)
1. Characteristics, Management, and Prognostic Implications of Adverse Effects of Immune Checkpoint Inhibitors: A Systematic Review.
Juan-Carpena G; Palazón-Cabanes JC; Blanes-Martínez M
Actas Dermosifiliogr; 2022 Apr; 113(4):376-387. PubMed ID: 35623728
[TBL] [Abstract][Full Text] [Related]
2. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU.
Riveiro-Barciela M; Carballal S; Díaz-González Á; Mañosa M; Gallego-Plazas J; Cubiella J; Jiménez-Fonseca P; Varela M; Menchén L; Sangro B; Fernández-Montes A; Mesonero F; Rodríguez-Gandía MÁ; Rivera F; Londoño MC
Gastroenterol Hepatol; 2024 Apr; 47(4):401-432. PubMed ID: 38228461
[TBL] [Abstract][Full Text] [Related]
3. How to recognize and manage skin toxicities associated with immune checkpoint inhibitors: a practical approach.
Kawsar A; Hussain K; Muinonen-Martin AJ; Fearfield L
Br J Dermatol; 2023 Oct; 189(Suppl 1):i3-i10. PubMed ID: 37903072
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis.
Wongvibulsin S; Pahalyants V; Kalinich M; Murphy W; Yu KH; Wang F; Chen ST; Reynolds K; Kwatra SG; Semenov YR
J Am Acad Dermatol; 2022 Mar; 86(3):563-572. PubMed ID: 33819538
[TBL] [Abstract][Full Text] [Related]
5. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.
Nikolaou VA; Apalla Z; Carrera C; Fattore D; Sollena P; Riganti J; Segura S; Freites-Martinez A; Lallas K; Romano MC; Oikonomou C; Starace M; Dimopoulos MA; Kyrgidis A; Lazaridou E; Giavedoni P; Annunziata MC; Peris K; Echeverría M; Lopez-Tujillo E; Syrigos K; Papageorgiou C; Podlipnik S; Fabbrocini G; Torre AC; Kemanetzi C; Villa-Crespo L; Lallas A; Stratigos AJ; Sibaud V
Br J Dermatol; 2022 Dec; 187(6):962-969. PubMed ID: 35861701
[TBL] [Abstract][Full Text] [Related]
6. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
Bhatlapenumarthi V; Patwari A; Harb AJ
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2789-2800. PubMed ID: 33774736
[TBL] [Abstract][Full Text] [Related]
7. Management of immune checkpoint inhibitor-related rheumatic adverse events.
Zhou J; Wang H; Guo X; Wang Q; Duan L; Si X; Zhang L; Liu X; Li Y; Zhang W; Zhang L
Thorac Cancer; 2020 Jan; 11(1):198-202. PubMed ID: 31762209
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
[TBL] [Abstract][Full Text] [Related]
9. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
Bhardwaj M; Chiu MN; Pilkhwal Sah S
Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous adverse events associated with immune checkpoint blockade: A systematic review and meta-analysis.
Han Y; Wang J; Xu B
Crit Rev Oncol Hematol; 2021 Jul; 163():103376. PubMed ID: 34087346
[TBL] [Abstract][Full Text] [Related]
11. Immune-related adverse events associated with immune checkpoint inhibitors in patients with cancer.
Sengul Samanci N; Cikman DI; Oruc K; Bedir S; Çelik E; Degerli E; Derin S; Demirelli FH; Özgüroğlu M
Tumori; 2021 Aug; 107(4):304-310. PubMed ID: 32935638
[TBL] [Abstract][Full Text] [Related]
12. Management of immune checkpoint inhibitor-related dermatologic adverse events.
Si X; He C; Zhang L; Liu X; Li Y; Wang H; Guo X; Zhou J; Duan L; Wang M; Zhang L
Thorac Cancer; 2020 Feb; 11(2):488-492. PubMed ID: 31814310
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article.
Chen CH; Yu HS; Yu S
Curr Oncol; 2022 Apr; 29(4):2871-2886. PubMed ID: 35448208
[TBL] [Abstract][Full Text] [Related]
14. Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy.
Ghisoni E; Wicky A; Bouchaab H; Imbimbo M; Delyon J; Gautron Moura B; Gérard CL; Latifyan S; Özdemir BC; Caikovski M; Pradervand S; Tavazzi E; Gatta R; Marandino L; Valabrega G; Aglietta M; Obeid M; Homicsko K; Mederos Alfonso NN; Zimmermann S; Coukos G; Peters S; Cuendet MA; Di Maio M; Michielin O
Eur J Cancer; 2021 May; 149():153-164. PubMed ID: 33865201
[TBL] [Abstract][Full Text] [Related]
15. Safety of current immune checkpoint inhibitors in non-small cell lung cancer.
Abdayem P; Planchard D
Expert Opin Drug Saf; 2021 Jun; 20(6):651-667. PubMed ID: 33393387
[No Abstract] [Full Text] [Related]
16. Rheumatic immune-related adverse events induced by immune checkpoint inhibitors.
Zhong H; Zhou J; Xu D; Zeng X
Asia Pac J Clin Oncol; 2021 Jun; 17(3):178-185. PubMed ID: 32717098
[TBL] [Abstract][Full Text] [Related]
17. Sarcoid-like Reactions to Immune Checkpoint Inhibitors.
Torrecilla-Vall-Llossera C; Jucglà Serra A; Molinero Caturla J; Moreno-Vílchez C; Penín Mosquera RM; Marcoval Caus J
Actas Dermosifiliogr; 2024 Jan; 115(1):80-83. PubMed ID: 37482293
[TBL] [Abstract][Full Text] [Related]
18. The Inconsistent and Inadequate Reporting Of Immune-Related Adverse Events in PD-1/PD-L1 Inhibitors: A Systematic Review of Randomized Controlled Clinical Trials.
Xie T; Zhang Z; Qi C; Lu M; Zhang X; Li J; Shen L; Peng Z
Oncologist; 2021 Dec; 26(12):e2239-e2246. PubMed ID: 34396642
[TBL] [Abstract][Full Text] [Related]
19. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
20. Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections.
Lu M; Zhang L; Li Y; Wang H; Guo X; Zhou J; Duan L; Si X; Xu Y; Zhang L
Thorac Cancer; 2020 Mar; 11(3):805-809. PubMed ID: 31970940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
